Data Insights

Saroglitazar by Zydus Therapeutics for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)....

Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Data Insights

Saroglitazar by Zydus Therapeutics for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Data Insights

Saroglitazar by Zydus Therapeutics for Cholestasis: Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase I for Cholestasis. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Cholestasis

Data Insights

Saroglitazar by Zydus Therapeutics for Primary Sclerosing Cholangitis: Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase I for Primary Sclerosing Cholangitis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Primary Sclerosing Cholangitis

Data Insights

Saroglitazar by Zydus Therapeutics for Liver Diseases: Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase I for Liver Diseases. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Liver Diseases

Data Insights

Saroglitazar by Zydus Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....

Likelihood of Approval and Phase Transition Success Rate Model - Saroglitazar in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)

Data Insights

Saroglitazar by Zydus Therapeutics for Polycystic Ovarian Syndrome: Likelihood of Approval

Saroglitazar is under clinical development by Zydus Therapeutics and currently in Phase II for Polycystic Ovarian Syndrome. According to GlobalData,...

Data Insights

Saroglitazar by Zydus Lifesciences for Hypertriglyceridemia: Likelihood of Approval

Saroglitazar is under clinical development by Zydus Lifesciences and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II...